Thyroid Gland Carcinoma

68Ga-NOTA-3P-TATE-RGD PET/CT is feasible for radioactive-iodine-negative DTC, providing complementary diagnostic information to 18F-FDG with enhanced detection of bone and brain metastases. The intense uptake observed in lesions with TERT-associated aggressive subtypes supports potential utility for specific disease identification.

When evaluating a subcarinal mediastinal mass following thyroid cancer surgery, it is important to include vascular lesions, such as BAAs, in the differential diagnosis, although these are rare. This case demonstrates that minimally invasive thoracoscopic resection provides both diagnostic confirmation and therapeutic benefits when preoperative diagnosis remains uncertain.

With levothyroxine and growth hormone treatment, pituitary hyperplasia regressed, and height increased by 15 cm in 1 year...Oncocytic thyroid carcinoma is rare in children, and its coexistence with hypothyroidism is unusual. This case emphasizes the importance of thyroid function testing in children with growth failure and sellar lesions, and vigilance in evaluating pediatric thyroid nodules given their elevated risk of malignancy.

P=N/A, N=2000, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027

Our study reveals a myeloid-centered regulatory network in thyroid cancer and highlights TNFSF12 as a context-dependent oncogene, offering novel insights into targeted therapy and immunotherapeutic strategies.

RET activation is a complex process involving multiple intracellular events, including calcium ion binding, glial cell line‑derived neurotrophic factor family ligand binding, and RET receptor aggregation, dimerization and autophosphorylation. The present study reviews the structure and function of the RET proto‑oncogene and its pathogenic roles in various TC subtypes.

Lenvatinib therapy was initiated at the previous hospital, resulting in tumor shrinkage, and total thyroidectomy was performed 62 days after the initiation of treatment...We report a case of poorly differentiated thyroid carcinoma with an SMARCB1 mutation. The accumulation of similar cases and additional immunohistochemical evaluations of past specimens may contribute to the development of targeted therapeutic strategies.

This study provides exploratory genetic and clinical evidence supporting a causal, protective role for specific peripheral and tumor-infiltrating B-cell subsets in PTC. Naïve B cells and CD27+ unswitched memory B cells are linked to indolent tumor behavior and favorable prognosis, highlighting their potential as biomarkers for risk stratification and non-invasive monitoring in PTC management.

In addition, peripheral immune alterations and immune-related gene activation suggest potential synergy between MWA and immune checkpoint blockade. Collectively, MWA not only provides effective local tumor destruction but also reshapes the tumor immune microenvironment, offering a rationale for combined thermal and immunotherapeutic strategies in thyroid oncology.

P=N/A, N=9, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026

P=N/A, N=15, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting